Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda.

3HP is being rolled out for TB prevention in high burden countries. We describe the incidence and clinical management of adverse events in a real-world clinical setting among people living with HIV participating in a pragmatic implementation study in Uganda.